CoChat

The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK

Open access
Zhang, Chen-Song, Li, Mengqi, Wang, Yu, Li, Xiaoyang, Zong, Yue, Long, Shating, Zhang, Mingliang, Feng, Jin-Wei, Wei, Xiaoyan, Liu, Yan-Hui, Zhang, Baoding, Wu, Jianfeng, Zhang, Cixiong, Lian, Wenhua, Ma, Teng, Tian, Xiao, Qu, Qi, Yu, Yaxin, Xiong, Jinye, Liu, Dong-Tai, Wu, Zhenhua, Zhu, Mingxia, Xie, Changchuan, Wu, Yaying, Xu, Zheni, Yang, Chunyan, Chen, Junjie, Huang, Guohong, He, Qingxia, Huang, Xi, Zhang, Lei, Sun, Xiufeng, Liu, Qingfeng, Ghafoor, Abdul, Gui, Fu, Zheng, Kaili, Wang, Wen, Wang, Zhi-Chao, Yu, Yong, Zhao, Qingliang, Lin, Shu-Yong, Wang, Zhi-Xin, Piao, Hai-Long, Deng, Xianming, Lin, Sheng-Cai · 2022 · Nature Metabolism
Cited by 99

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

The activity of 5′-adenosine monophosphate-activated protein kinase (AMPK) is inversely correlated with the cellular availability of glucose. When glucose levels are low, the glycolytic enzyme aldolase is not bound to fructose-1,6-bisphosphate (FBP) and, instead, signals to activate lysosomal AMPK. Here, we show that blocking FBP binding to aldolase with the small molecule aldometanib selectively activates the lysosomal pool of AMPK and has beneficial metabolic effects in rodents. We identify aldometanib in a screen for aldolase inhibitors and show that it prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK, thereby mimicking a cellular state of glucose starvation. In male mice, aldometanib elicits an insulin-independent glucose-lowering effect, without causing hypoglycaemia. Aldometanib also alleviates fatty liver and nonalcoholic steatohepatitis in obese male rodents. Moreover, aldometanib extends lifespan and healthspan in both Caenorhabditis elegans and mice. Taken together, aldometanib mimics and adopts the lysosomal AMPK activation pathway associated with glucose starvation to exert physiological roles, and might have potential as a therapeutic for metabolic disorders in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-022-00640-7

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 102

  1. Herzig, S. & Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/nrm.2017.95 (2017). · DOI · Paper page
  2. Carling, D., Clarke, P. R., Zammit, V. A. & Hardie, D. G. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur. J. Biochem. 186, 129–136 (1989). · DOI · Paper page
  3. Oakhill, J. S. et al. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl Acad. Sci. USA 107, 19237–19241 (2010). · DOI · Paper page
  4. Gu, X. et al. Deconvoluting AMP-activated protein kinase (AMPK) adenine nucleotide binding and sensing. J. Biol. Chem. 292, 12653–12666 (2017). · DOI
  5. Zong, Y. et al. Hierarchical activation of compartmentalized pools of AMPK depends on severity of nutrient or energy stress. Cell Res. 29, 460–473 (2019). · DOI · Paper page
  6. Marques, P. et al. Essential role of glucokinase in the protection of pancreatic beta cells to the glucose energetic status. Cell Death Discov. 5, 138 (2019). · DOI
  7. Drake, J. C. et al. Mitochondria-localized AMPK responds to local energetics and contributes to exercise and energetic stress-induced mitophagy. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2025932118 (2021). · DOI · Paper page
  8. Schmitt, D. L. et al. Spatial regulation of AMPK signaling revealed by a sensitive kinase activity reporter. Nat. Commun. 13, 3856 (2021). · DOI
  9. Zhang, C. S. et al. The lysosomal v-ATPase–Ragulator complex Is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab. 20, 526–540 (2014). · DOI · Paper page
  10. Zhang, C. S. et al. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature 548, 112–116 (2017). · DOI · Paper page
  11. Li, M. et al. Transient receptor potential V channels are essential for glucose sensing by aldolase and AMPK. Cell Metab. 30, 508–524 (2019). · DOI · Paper page
  12. Zhang, Y. L. et al. AMP as a low-energy charge signal autonomously initiates assembly of AXIN–AMPK–LKB1 complex for AMPK activation. Cell Metab. 18, 546–555 (2013). · DOI · Paper page
  13. Salt, I. P., Johnson, G., Ashcroft, S. J. H. & Hardie, D. G. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem. J. 335, 533–539 (1998). · DOI · Paper page
  14. Sakamoto, K. et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKα2 but not AMPKα1. Am. J. Physiol. Endocrinol. Metab. 290, E780–E788 (2006).
  15. Liang, J. et al. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat. Commun. 6, 7926 (2015). · DOI · Paper page
  16. Li, Y. et al. AMPK phosphorylates and Inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13, 376–388 (2011). · DOI · Paper page
  17. Chen, S. et al. Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem. J. 409, 449–459 (2008). · DOI · Paper page
  18. Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132–141 (2011). · DOI · Paper page
  19. Kim, J. et al. Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell 152, 290–303 (2013). · DOI · Paper page
  20. Day, E. A., Ford, R. J. & Steinberg, G. R. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metab. 28, 545–560 (2017). · DOI · Paper page
  21. Steinberg, G. R. & Carling, D. AMP-activated protein kinase: the current landscape for drug development. Nat. Rev. Drug Discov. 18, 527–551 (2019). · DOI · Paper page
  22. Olivier, S., Foretz, M. & Viollet, B. Promise and challenges for direct small-molecule AMPK activators. Biochem. Pharmacol. 153, 147–158 (2018). · DOI · Paper page
  23. Brass, E. P. & Hoppel, C. L. Mitochondria as targets of drug toxicity: lessons from the R118 phase I experience. Clin. Pharmacol. Ther. 98, 464–466 (2015). · DOI
  24. Low Wang, C. C., Galinkin, J. L. & Hiatt, W. R. Toxicity of a novel therapeutic agent targeting mitochondrial complex I. Clin. Pharmacol. Ther. 98, 551–559 (2015). · DOI
  25. Kjobsted, R. et al. Intact regulation of the AMPK signaling network in response to exercise and insulin in skeletal muscle of male patients with Type 2 diabetes: illumination of AMPK activation in recovery from exercise. Diabetes 65, 1219–1230 (2016). · DOI · Paper page
  26. Cool, B. et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3, 403–416 (2006). · DOI · Paper page
  27. Ford, R. J. et al. Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochemical J. 468, 125–132 (2015). · DOI · Paper page
  28. Esquejo, R. M. et al. Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models. EBioMedicine 31, 122–132 (2018). · DOI · Paper page
  29. Gluais-Dagorn, P. et al. Direct AMPK activation corrects NASH in rodents through metabolic effects and direct action on inflammation and fibrogenesis. Hepatol Commun. https://doi.org/10.1002/hep4.1799 (2021). · DOI · Paper page
  30. Morris, A. J. & Tolan, D. R. Site-directed mutagenesis identifies aspartate 33 as a previously unidentified critical residue in the catalytic mechanism of rabbit aldolase A. J. Biol. Chem. 268, 1095–1100 (1993). · DOI
  31. Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750–1759 (2004). · DOI · Paper page
  32. Friesner, R. A. et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177–6196 (2006). · DOI · Paper page
  33. St-Jean, M., Lafrance-Vanasse, J., Liotard, B. & Sygusch, J. High-resolution reaction intermediates of rabbit muscle fructose-1,6-bisphosphate aldolase: substrate cleavage and induced fit. J. Biol. Chem. 280, 27262–27270 (2005). · doi:10.1074/jbc.m502413200
  34. Kitajima, Y., Takasaki, Y., Takahashi, I. & Hori, K. Construction and properties of active chimeric enzymes between human aldolases A and B. Analysis of molecular regions which determine isozyme-specific functions. J. Biol. Chem. 265, 17493–17498 (1990). · doi:10.1016/s0021-9258(18)38191-2
  35. Morris, A. J. & Tolan, D. R. Lysine-146 of rabbit muscle aldolase is essential for cleavage and condensation of the C3-C4 bond of fructose 1,6-bisphosphate. Biochemistry 33, 12291–12297 (1994). · DOI
  36. Morris, A. J., Davenport, R. C. & Tolan, D. R. A lysine to arginine substitution at position 146 of rabbit aldolase A changes the rate-determining step to Schiff base formation. Protein Eng. 9, 61–67 (1996). · doi:10.1093/protein/9.1.61
  37. Blonski, C., De Moissac, D., Perie, J. & Sygusch, J. Inhibition of rabbit muscle aldolase by phosphorylated aromatic compounds. Biochemical J. 323, 71–77 (1997). · doi:10.1042/bj3230071
  38. Maurady, A., Zdanov, A., de Moissac, D., Beaudry, D. & Sygusch, J. A conserved glutamate residue exhibits multifunctional catalytic roles in d-fructose-1,6-bisphosphate aldolases. J. Biol. Chem. 277, 9474–9483 (2002). · doi:10.1074/jbc.m107600200
  39. Cousin, M. A. & Nicholls, D. G. Synaptic vesicle recycling in cultured cerebellar granule cells: role of vesicular acidification and refilling. J. Neurochem. 69, 1927–1935 (1997). · DOI
  40. Woods, A. et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2, 21–33 (2005). · DOI · Paper page
  41. Shestov, A. A. et al. Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. Elife https://doi.org/10.7554/eLife.03342 (2014). · DOI · Paper page
  42. Li, M. et al. Aldolase is a sensor for both low and high glucose, linking to AMPK and mTORC1. Cell Res. https://doi.org/10.1038/s41422-020-00456-8 (2020). · DOI
  43. Marsin, A. S. et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 10, 1247–1255 (2000). · DOI · Paper page
  44. Markmann, S. et al. Quantitative proteome analysis of mouse liver lysosomes provides evidence for mannose 6-phosphate-independent targeting mechanisms of acid hydrolases in mucolipidosis II. Mol. Cell Proteomics 16, 438–450 (2017). · DOI · Paper page
  45. Leighton, F. et al. The large-scale separation of peroxisomes, mitochondria and lysosomes from the livers of rats injected with triton WR-1339. Improved isolation procedures, automated analysis, biochemical and morphological properties of fractions. J. Cell Biol. 37, 482–513 (1968). · DOI · Paper page
  46. Koivusalo, M., Steinberg, B. E., Mason, D. & Grinstein, S. In situ measurement of the electrical potential across the lysosomal membrane using FRET. Traffic 12, 972–982 (2011). · DOI
  47. Cokorinos, E. C. et al. Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-human primates and mice. Cell Metab. 25, 1147–1159 (2017). · DOI · Paper page
  48. Steneberg, P. et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight https://doi.org/10.1172/jci.insight.99114 (2018). · DOI · Paper page
  49. Woods, A. et al. Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep. 18, 3043–3051 (2017). · DOI · Paper page
  50. Boudaba, N. et al. AMPK reactivation suppresses hepatic steatosis but its downregulation does not promote fatty liver development. EBioMedicine 28, 194–209 (2018). · DOI · Paper page
  51. Garcia, D. et al. Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD. Cell Rep. 26, 192–208 (2019). · DOI · Paper page
  52. Sakers, A., De Siqueira, M. K., Seale, P. & Villanueva, C. J. Adipose-tissue plasticity in health and disease. Cell 185, 419–446 (2022). · DOI · Paper page
  53. Zhao, P. et al. An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367, 652–660 (2020). · DOI · Paper page
  54. Song, L. et al. FGF4 protects the liver from non-alcoholic fatty liver disease by activating the AMPK–caspase 6 signal axis. Hepatology https://doi.org/10.1002/hep.32404 (2022). · DOI
  55. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005). · DOI · Paper page
  56. Bagherniya, M., Butler, A. E., Barreto, G. E. & Sahebkar, A. The effect of fasting or calorie restriction on autophagy induction: a review of the literature. Ageing Res. Rev. 47, 183–197 (2018). · DOI · Paper page
  57. Nakamura, N., Matsuura, A., Wada, Y. & Ohsumi, Y. Acidification of vacuoles is required for autophagic degradation in the yeast, Saccharomyces cerevisiae. J. Biochem. 121, 338–344 (1997). · DOI · Paper page
  58. Salt, I. P. & Hardie, D. G. AMP-activated protein kinase: an ubiquitous signaling pathway with key roles in the cardiovascular system. Circ. Res. 120, 1825–1841 (2017). · DOI · Paper page
  59. Arad, M., Seidman, C. E. & Seidman, J. G. AMP-activated protein kinase in the heart: role during health and disease. Circ. Res. 100, 474–488 (2007). · DOI · Paper page
  60. Yavari, A. et al. Chronic activation of γ2 AMPK induces obesity and reduces beta cell function. Cell Metab. 23, 821–836 (2016). · DOI · Paper page
  61. Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918–922 (2012). · DOI · Paper page
  62. Goldfine, A. B. et al. The effects of salsalate on glycaemic control in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med. 152, 346–357 (2010). · DOI · Paper page
  63. Meex, R. C., Phielix, E., Moonen-Kornips, E., Schrauwen, P. & Hesselink, M. K. Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions. J. Clin. Endocrinol. Metab. 96, 1415–1423 (2011). · DOI
  64. Fouqueray, P. et al. Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study. Cell Rep. Med. 2, 100474 (2021). · DOI
  65. Cusi, K. et al. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Gastroenterol. Hepatol. 6, 889–902 (2021). · DOI · Paper page
  66. Hammerschmidt, P. et al. CerS6-derived sphingolipids interact with Mff and promote mitochondrial fragmentation in obesity. Cell 177, 1536–1552 (2019). · DOI · Paper page
  67. Wang, F. et al. Saturated very-long-chain fatty acid configures glycosphingolipid for lysosome homeostasis in long-lived C. elegans. Nat. Commun. 12, 5073 (2021). · DOI
  68. Grandjean, G. et al. Definition of a novel feed-forward mechanism for glycolysis–HIF1α signaling in hypoxic tumors highlights aldolase A as a therapeutic target. Cancer Res. 76, 4259–4269 (2016). · DOI · Paper page
  69. Gizak, A. et al. Targeting a moonlighting function of aldolase induces apoptosis in cancer cells. Cell Death Dis. 10, 712 (2019). · DOI
  70. Bai, D. et al. ALDOA maintains NLRP3 inflammasome activation by controlling AMPK activation. Autophagy https://doi.org/10.1080/15548627.2021.1997051 (2021). · DOI
  71. De Rosa, M. J. et al. The flight response impairs cytoprotective mechanisms by activating the insulin pathway. Nature 573, 135–138 (2019). · DOI
  72. Yuan, J. et al. Two conserved epigenetic regulators prevent healthy ageing. Nature 579, 118–122 (2020). · DOI
  73. Heron, P. W., Abellan-Flos, M., Salmon, L. & Sygusch, J. Bisphosphonate inhibitors of mammalian glycolytic aldolase. J. Med. Chem. 61, 10558–10572 (2018). · doi:10.1021/acs.jmedchem.8b01000
  74. Park, S. J. et al. DNA-PK promotes the mitochondrial, metabolic, and physical decline that occurs during aging. Cell Metab. 25, 1135–1146 (2017). · DOI · Paper page
  75. Luo, H. et al. AIDA selectively mediates downregulation of fat synthesis enzymes by ERAD to retard intestinal fat absorption and prevent obesity. Cell Metab. 27, 843–853 (2018). · DOI
  76. Hui, X. et al. Adipocyte SIRT1 controls systemic insulin sensitivity by modulating macrophages in adipose tissue. EMBO Rep. 18, 645–657 (2017). · DOI · Paper page
  77. Zhang, M. et al. Loss of β-arrestin2 mediates pancreatic-islet dysfunction in mice. Biochem. Biophys. Res. Commun. 435, 345–349 (2013). · DOI
  78. Huang, D. et al. Intravital whole-process monitoring thermo-chemotherapy via 2D silicon nanoplatform: a macro guidance and long-term microscopic precise imaging strategy. Adv. Sci. 8, e2101242 (2021). · DOI
  79. Qiu, Q. et al. Noninvasive dual-modality photoacoustic-ultrasonic imaging to detect mammalian embryo abnormalities after prenatal exposure to methylmercury chloride (MMC): a mouse study. Environ. Health Perspect. 130, 27002 (2022). · DOI
  80. Liu, P. et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature 546, 107–112 (2017). · DOI · Paper page
  81. Chen, J. et al. Metformin extends C. elegans lifespan through lysosomal pathway. Elife https://doi.org/10.7554/eLife.31268 (2017). · DOI · Paper page
  82. Fang, E. F. et al. NAD+ replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016). · DOI · Paper page
  83. Yen, K. et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging 12, 11185–11199 (2020). · DOI · Paper page
  84. Rando, T. A. & Blau, H. M. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J. cell Biol. 125, 1275–1287 (1994). · DOI · Paper page
  85. Nargund, A. M., Fiorese, C. J., Pellegrino, M. W., Deng, P. & Haynes, C. M. Mitochondrial and nuclear accumulation of the transcription factor ATFS-1 promotes OXPHOS recovery during the UPR(mt). Mol. cell 58, 123–133 (2015). · DOI · Paper page
  86. Zhang, Q. et al. The memory of neuronal mitochondrial stress is inherited transgenerationally via elevated mitochondrial DNA levels. Nat. Cell Biol. 23, 870–880 (2021). · DOI
  87. Quiros, P. M., Goyal, A., Jha, P. & Auwerx, J. Analysis of mtDNA/nDNA ratio in mice. Curr. Protoc. Mouse Biol. 7, 47–54 (2017). · DOI · Paper page
  88. Ye, D. et al. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil–macrophage crosstalk via the induction of CXCR2. J. Hepatol. 65, 988–997 (2016). · DOI · Paper page
  89. Mair, F. et al. Extricating human tumour immune alterations from tissue inflammation. Nature 605, 728–735 (2022). · DOI
  90. Mair, F. & Tyznik, A. J. High-dimensional immunophenotyping with fluorescence-based cytometry: a practical guidebook. Methods Mol. Biol. 2032, 1–29 (2019). · DOI
  91. Liechti, T. et al. An updated guide for the perplexed: cytometry in the high-dimensional era. Nat. Immunol. 22, 1190–1197 (2021). · DOI
  92. Preez, G. D. et al. Oxygen consumption rate of Caenorhabditis elegans as a high-throughput endpoint of toxicity testing using the Seahorse XFe96 Extracellular Flux Analyzer. Sci. Rep. 10, 4239 (2020). · DOI
  93. Kuznetsov, A. V. et al. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells. Nat. Protoc. 3, 965–976 (2008). · DOI · Paper page
  94. Kobayashi, T. et al. Separation and characterization of late endosomal membrane domains. J. Biol. Chem. 277, 32157–32164 (2002). · DOI · Paper page
  95. Penhoet, E. E. & Rutter, W. J. Detection and isolation of mammalian fructose-diphosphate aldolases. Methods Enzymol. 42, 240–249 (1975). · DOI
  96. Choi, K. H. et al. Structure of a fructose-1,6-bis(phosphate) aldolase liganded to its natural substrate in a cleavage-defective mutant at 2.3 Å. Biochemistry 38, 12655–12664 (1999). · doi:10.1021/bi9828371
  97. Say, R. F. & Fuchs, G. Fructose 1,6-bisphosphate aldolase/phosphatase may be an ancestral gluconeogenic enzyme. Nature 464, 1077–1081 (2010). · DOI · Paper page
  98. Hu, H. et al. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 164, 433–446 (2016). · DOI · Paper page
  99. Bajad, S. U. et al. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J. Chromatogr. A 1125, 76–88 (2006). · DOI · Paper page
  100. Hui, S. et al. Quantitative fluxomics of circulating metabolites. Cell Metab. 32, 676–688 (2020). · DOI · Paper page
  101. Choi, K. H., Shi, J., Hopkins, C. E., Tolan, D. R. & Allen, K. N. Snapshots of catalysis: the structure of fructose-1,6-(bis)phosphate aldolase covalently bound to the substrate dihydroxyacetone phosphate. Biochemistry 40, 13868–13875 (2001). · doi:10.1021/bi0114877
  102. Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211–D1217 (2019). · DOI · Paper page

Cited by

See all 99

Metadata

Authors
Zhang, C.-S., Li, M., Wang, Y., Li, X., Zong, Y., Long, S., Zhang, M., Feng, J.-W., Wei, X., Liu, Y.-H., Zhang, B., Wu, J., Zhang, C., Lian, W., Ma, T., Tian, X., Qu, Q., Yu, Y., Xiong, J., Liu, D.-T., Wu, Z., Zhu, M., Xie, C., Wu, Y., Xu, Z., Yang, C., Chen, J., Huang, G., He, Q., Huang, X., Zhang, L., Sun, X., Liu, Q., Ghafoor, A., Gui, F., Zheng, K., Wang, W., Wang, Z.-C., Yu, Y., Zhao, Q., Lin, S.-Y., Wang, Z.-X., Piao, H.-L., Deng, X., & Lin, S.-C.
Venue
Nature Metabolism
Published
2022-10-10
Volume
4
Issue
10
Pages
1369-1401
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4304080692
Cited by
99
References
43
FWCI
5.04
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Ministry of Education of the People’s Republic of China (#BP2018017)
  • Xiamen University (#20720200069, 2020Y1021, #20720190084)
  • National Natural Science Foundation of China (#82088102, #91854208, #92157001, #31922034, #92057204, #32070753, #22025702, #82021003, #82151211, #91853203)
  • Ministry of Science and Technology of the People’s Republic of China (2020YFA0803402, 2017YFA0504504)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. https://app.cochat.ai/papers/10.1038/s42255-022-00640-7
The paper
Zhang, C.-S., Li, M., Wang, Y., Li, X., Zong, Y., Long, S., Zhang, M., Feng, J.-W., Wei, X., Liu, Y.-H., Zhang, B., Wu, J., Zhang, C., Lian, W., Ma, T., Tian, X., Qu, Q., Yu, Y., Xiong, J., . . . Lin, S.-C. (2022). The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nature Metabolism. https://doi.org/10.1038/s42255-022-00640-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.